Developer docs
API playgroundTry for free, no card

Search company profiles

LSI (Life Science Innovations Fund)

Full company profile

uuid000x7rs

Namestring
LSI (Life Science Innovations Fund)
Legal namestring
Life Science Innovations sp. z o.o. sp. k.
Websiteurl
lsifund.pl
Company typeenum
Private
Founded yearint
2018
Descriptiontext

LSI (Life Science Innovations Fund) is a pre-seed and seed-stage venture capital fund and incubator headquartered in Białystok, Poland, structured as a Polish limited partnership (Life Science Innovations sp. z o.o. sp. k.). The fund invests in early-stage life sciences startups across four verticals: healthcare (preventive medicine, cost-reduction technologies, patient solutions), environmental protection (climate-positive, clean energy, biodiversity), biotech (laboratory diagnostics, agriculture, food production), and medtech (medical devices, biomaterials, health IT). LSI's stated mission is to incubate disruptive life sciences innovations and scale them into global challengers, sourcing deals primarily through a website-based project submission process where founders submit pitch decks for evaluation.

The fund has deployed capital across approximately 11 portfolio companies, including Lumisep, Wheelstair, ISN Pharma, Lifeflow, AIDMED, Bioseco, MeWheel, Brainscan, ABAStroke, Hagi, and Health2Organ. LSI is led by a four-person team: CEO Paweł Wilski (MSc), General Partner Adam Cudny (MSc, CIMA, ACCA), and Investment Committee members Marcin Szumowski (PhD) and Piotr Jeleński (MSc, MBS). The fund's operations are co-financed by the European Regional Development Fund under the Smart Growth Operational Programme 2014-2020, and the fund publishes SFDR/ESG disclosures, positioning it within the EU sustainable finance framework.

As an investment vehicle, LSI generates returns through equity stakes in portfolio companies rather than product or service revenue. The fund has demonstrated access to international syndicates via a 2026 co-investment with TPG Life Sciences Innovations in Odyssey Therapeutics' $304 million IPO. Distribution is regional (Europe, anchored in Poland), with deal sourcing concentrated on a direct website submission channel rather than institutional LP-raised capital of meaningful scale.

Short descriptiontext

LSI is a pre-seed and seed-stage venture capital fund based in Białystok, Poland, that incubates and invests in early-stage life sciences startups across healthcare, biotech, medtech, and environmental protection verticals, with operations co-financed by the European Regional Development Fund.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBialystok, Poland
HQ citystring
Bialystok
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital fund, life sciences investment, seed stage funding, startup incubation, healthcare venture capital
Industry3 codes
1Early-Stage Venture Capital (Series A/B)
CodeFSANAAABPrimaryYes
2Climate / Clean Tech & Decarbonization Funds
CodeFSANAJAAPrimaryNo
3SDG / Thematic Sustainable Investment Funds
CodeFSANAJANPrimaryNo
NAICS code1 code
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Life Sciences Investment
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

LSI Fund generates returns through equity investments in early-stage life sciences companies, incubating them into global businesses. The fund operates as an investor and incubator, providing capital and support to portfolio companies in exchange for equity stakes.

lsifund.pl
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LSI Fund is a Polish venture capital and incubation fund that provides pre-seed and seed stage capital investments to early-stage life sciences startups. The fund invests in companies operating across four focus areas — healthcare, environmental protection, biotech, and medtech — and incubates them into global challengers through ongoing capital, mentorship, and scaling support.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LSI (Life Science Innovations Fund) is a venture capital and incubation fund that invests in life sciences startups across four focus areas: healthcare (preventive medicine, cost-reduction technology, patient solutions), environmental protection (climate-positive innovations, clean energy, sustainability), biotech (laboratory diagnostics, agriculture, food production technology), and medtech (medical devices, diagnostics, biomaterials, health IT). The fund does not offer a single unified product but rather provides investment, incubation, and scaling support to portfolio companies including Lumisep, Wheelstair, ISN Pharma, LifeFlow, AIDMED, BioSeco, BrainScan, ABAStroke, Hagi, and Health2Organ.

Product and service1 record
1Investment and Incubation Services
CategoryVenture Capital / Incubation
Description

Capital investment and incubation services provided to early-stage life sciences startups in healthcare, environmental protection, biotech, and medtech sectors. Services include evaluation of project submissions with pitch decks, equity investment, and ongoing support during the investment period to scale portfolio companies into global challengers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Amsterdam-based life sciences venture capital arm of EQT, investing in European biotech, medtech, and digital health. Direct peer — comparable European footprint, life sciences focus, and growth-stage orientation.

TypeDirect peer
Description

Paris-based VC with a dedicated health and life sciences franchise covering biotech, medtech, and digital health. Direct peer — comparable life sciences specialism and European presence.

TypeDirect peer
Description

Netherlands-based European life sciences VC investing across development stages with focus on biotech and medical devices. Direct comparable — same European life sciences VC thesis, similar stage range, comparable thematic scope.

TypeRegional player
Description

Poland-based early-stage VC investing in tech-enabled businesses including healthtech and biotech adjacencies. Regional peer — Poland-domiciled, early-stage focus overlapping with LSI's geographic and stage profile.

TypeRegional player
Description

Poland-based early- and growth-stage VC with healthtech and life sciences exposure. Regional peer — same Polish base and early-stage orientation, providing regional benchmarking for deal sourcing and exit dynamics.

TypeDirect peer
Description

Paris-based European life sciences VC investing in biotech, medtech, and digital health across early and growth stages. Direct peer — comparable life sciences thematic breadth and European scope.

TypeDirect peer
Description

Dutch-based early-stage life sciences VC focused on biotech and medtech in the Benelux and broader Europe. Direct peer — early-stage life sciences specialism directly aligns with LSI's pre-seed/seed mandate.

TypeRegional player
Description

Poland-based venture capital firm with early-stage investments across sectors including digital health and life sciences. Regional peer — same Polish geography, comparable early-stage orientation, though broader sector mandate than LSI.

TypeDirect peer
Description

Swiss/UK-based life sciences VC investing in early- and late-stage therapeutics and medical technology companies across Europe. Direct peer — same life sciences specialism with comparable stage coverage and European geographic focus.

TypeDirect peer
Description

Paris-based, Europe-leading life sciences venture capital firm investing across all stages (seed through late-stage) of therapeutics and medtech. Directly comparable as a Europe-based life sciences specialist VC with comparable thematic breadth (biopharma, medtech, digital health).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment14 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LSI (Life Science Innovations Fund)

Venture Capital / Life Sciences Investmentlsifund.pl

LSI is a pre-seed and seed-stage venture capital fund based in Białystok, Poland, that incubates and invests in early-stage life sciences startups across healthcare, biotech, medtech, and environmental protection verticals, with operations co-financed by the European Regional Development Fund.

What LSI (Life Science Innovations Fund) does

LSI (Life Science Innovations Fund) is a pre-seed and seed-stage venture capital fund and incubator headquartered in Białystok, Poland, structured as a Polish limited partnership (Life Science Innovations sp. z o.o. sp. k.). The fund invests in early-stage life sciences startups across four verticals: healthcare (preventive medicine, cost-reduction technologies, patient solutions), environmental protection (climate-positive, clean energy, biodiversity), biotech (laboratory diagnostics, agriculture, food production), and medtech (medical devices, biomaterials, health IT). LSI's stated mission is to incubate disruptive life sciences innovations and scale them into global challengers, sourcing deals primarily through a website-based project submission process where founders submit pitch decks for evaluation.

The fund has deployed capital across approximately 11 portfolio companies, including Lumisep, Wheelstair, ISN Pharma, Lifeflow, AIDMED, Bioseco, MeWheel, Brainscan, ABAStroke, Hagi, and Health2Organ. LSI is led by a four-person team: CEO Paweł Wilski (MSc), General Partner Adam Cudny (MSc, CIMA, ACCA), and Investment Committee members Marcin Szumowski (PhD) and Piotr Jeleński (MSc, MBS). The fund's operations are co-financed by the European Regional Development Fund under the Smart Growth Operational Programme 2014-2020, and the fund publishes SFDR/ESG disclosures, positioning it within the EU sustainable finance framework.

As an investment vehicle, LSI generates returns through equity stakes in portfolio companies rather than product or service revenue. The fund has demonstrated access to international syndicates via a 2026 co-investment with TPG Life Sciences Innovations in Odyssey Therapeutics' $304 million IPO. Distribution is regional (Europe, anchored in Poland), with deal sourcing concentrated on a direct website submission channel rather than institutional LP-raised capital of meaningful scale.

LSI (Life Science Innovations Fund) firmographics

Firmographics
Name
LSI (Life Science Innovations Fund)
Legal name
Life Science Innovations sp. z o.o. sp. k.
Website
https://lsifund.pl
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
LSI is a pre-seed and seed-stage venture capital fund based in Białystok, Poland, that incubates and invests in early-stage life sciences startups across healthcare, biotech, medtech, and environmental protection verticals, with operations co-financed by the European Regional Development Fund.
Ownership category
akta.pro rank

LSI (Life Science Innovations Fund) industry classification

Industry
Product category
Venture Capital / Life Sciences Investment
NAICS
Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro primary industry
Early-Stage Venture Capital (Series A/B) (FSANAAAB)
akta.pro secondary industries
Climate / Clean Tech & Decarbonization Funds (FSANAJAA), SDG / Thematic Sustainable Investment Funds (FSANAJAN)

Keywords

  • Venture capital fund
  • Life sciences investment
  • Seed stage funding
  • Startup incubation
  • Healthcare venture capital

Where LSI (Life Science Innovations Fund) is headquartered

Location

Headquarters

HQ city
Bialystok
HQ country
Poland
HQ region
Europe

Offices1 record

Markets served

LSI (Life Science Innovations Fund) business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Investment Returns: LSI Fund generates returns through equity investments in early-stage life sciences companies, incubating them into global businesses. The fund operates as an investor and incubator, providing capital and support to portfolio companies in exchange for equity stakes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

LSI (Life Science Innovations Fund) product offering

Product offering

Core offering

LSI Fund is a Polish venture capital and incubation fund that provides pre-seed and seed stage capital investments to early-stage life sciences startups. The fund invests in companies operating across four focus areas — healthcare, environmental protection, biotech, and medtech — and incubates them into global challengers through ongoing capital, mentorship, and scaling support.

Product overview

LSI (Life Science Innovations Fund) is a venture capital and incubation fund that invests in life sciences startups across four focus areas: healthcare (preventive medicine, cost-reduction technology, patient solutions), environmental protection (climate-positive innovations, clean energy, sustainability), biotech (laboratory diagnostics, agriculture, food production technology), and medtech (medical devices, diagnostics, biomaterials, health IT). The fund does not offer a single unified product but rather provides investment, incubation, and scaling support to portfolio companies including Lumisep, Wheelstair, ISN Pharma, LifeFlow, AIDMED, BioSeco, BrainScan, ABAStroke, Hagi, and Health2Organ.

Differentiator

Problem solved

Functional benefit

Products and services

  • Investment and Incubation Services Capital investment and incubation services provided to early-stage life sciences startups in healthcare, environmental protection, biotech, and medtech sectors. Services include evaluation of project submissions with pitch decks, equity investment, and ongoing support during the investment period to scale portfolio companies into global challengers.

Companies that use LSI (Life Science Innovations Fund)

Customer profile

Segments1 record

Ideal customer profiles1 record

LSI (Life Science Innovations Fund) technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LSI (Life Science Innovations Fund) partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

LSI (Life Science Innovations Fund) competitors and assessment

Company assessment

Direct peers

  • EQT Life Sciences: Amsterdam-based life sciences venture capital arm of EQT, investing in European biotech, medtech, and digital health. Direct peer — comparable European footprint, life sciences focus, and growth-stage orientation.
  • Seventure Partners: Paris-based VC with a dedicated health and life sciences franchise covering biotech, medtech, and digital health. Direct peer — comparable life sciences specialism and European presence.
  • Forbion: Netherlands-based European life sciences VC investing across development stages with focus on biotech and medical devices. Direct comparable — same European life sciences VC thesis, similar stage range, comparable thematic scope.
  • Kurma Partners: Paris-based European life sciences VC investing in biotech, medtech, and digital health across early and growth stages. Direct peer — comparable life sciences thematic breadth and European scope.
  • BioGeneration Ventures: Dutch-based early-stage life sciences VC focused on biotech and medtech in the Benelux and broader Europe. Direct peer — early-stage life sciences specialism directly aligns with LSI's pre-seed/seed mandate.
  • Medicxi: Swiss/UK-based life sciences VC investing in early- and late-stage therapeutics and medical technology companies across Europe. Direct peer — same life sciences specialism with comparable stage coverage and European geographic focus.
  • Sofinnova Partners: Paris-based, Europe-leading life sciences venture capital firm investing across all stages (seed through late-stage) of therapeutics and medtech. Directly comparable as a Europe-based life sciences specialist VC with comparable thematic breadth (biopharma, medtech, digital health).

Regional players

  • Inovo VC: Poland-based early-stage VC investing in tech-enabled businesses including healthtech and biotech adjacencies. Regional peer — Poland-domiciled, early-stage focus overlapping with LSI's geographic and stage profile.
  • Movens Capital: Poland-based early- and growth-stage VC with healthtech and life sciences exposure. Regional peer — same Polish base and early-stage orientation, providing regional benchmarking for deal sourcing and exit dynamics.
  • SpeedUp Venture Capital Group: Poland-based venture capital firm with early-stage investments across sectors including digital health and life sciences. Regional peer — same Polish geography, comparable early-stage orientation, though broader sector mandate than LSI.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

LSI (Life Science Innovations Fund) financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LSI (Life Science Innovations Fund) leadership team

Management profile

Number of profiles

Profiles4 records

LSI (Life Science Innovations Fund) funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LSI (Life Science Innovations Fund) M&A and investment

M&A and investment

M&A

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LSI (Life Science Innovations Fund)

What does LSI (Life Science Innovations Fund) do?

LSI Fund is a Polish venture capital and incubation fund that provides pre-seed and seed stage capital investments to early-stage life sciences startups. The fund invests in companies operating across four focus areas — healthcare, environmental protection, biotech, and medtech — and incubates them into global challengers through ongoing capital, mentorship, and scaling support.

Is LSI (Life Science Innovations Fund) a public or private company?

LSI (Life Science Innovations Fund) is a private company. It is classified as management employee owned and is currently operating.

When was LSI (Life Science Innovations Fund) founded?

LSI (Life Science Innovations Fund) was founded in 2018. It employs 1 to 10 people.

Where is LSI (Life Science Innovations Fund) based?

LSI (Life Science Innovations Fund) is headquartered in Bialystok, Poland, in the Europe region.

How does LSI (Life Science Innovations Fund) make money?

One revenue line is on record: investment Returns.

Who are LSI (Life Science Innovations Fund)'s main competitors?

Direct peers on record are EQT Life Sciences, Seventure Partners, Forbion, Kurma Partners, BioGeneration Ventures, Medicxi and Sofinnova Partners. Regional players are Inovo VC, Movens Capital and SpeedUp Venture Capital Group.

Does LSI (Life Science Innovations Fund) have an API?

No public API is recorded for LSI (Life Science Innovations Fund).

What industry is LSI (Life Science Innovations Fund) in?

LSI (Life Science Innovations Fund)'s product category is Venture Capital / Life Sciences Investment. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAJAA, Climate / Clean Tech & Decarbonization Funds. Its NAICS code is 525990 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales